340B Advocacy Alliance Bulletin
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan. 1, 2026.
The Senate Committee on Health, Education, Labor and Pensions today held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on patients.
Senate HELP Committee to hold hearing on 340B program
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
In a letter responding to HRSA’s information collection request regarding the expected costs of its 340B Rebate Model Pilot Program, the AHA said 340B hospitals indicated that the operational costs associated with the rebate model could range from $150,000 to over $500,000 per hospital.
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements.
AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
AHA 340B Advocacy Alliance for September 8, 2025.
340B Advocacy Alliance Bulletin for September 5, 2025.
340B Advocacy Alliance Bulletin for September 3, 2025.